请使用支持JavaScript的浏览器!
主营:蛋白酶抑制剂,激酶抑制剂
℡ 4000-520-616
℡ 4000-520-616
LC Labs/O-3077 Obatoclax, Methanesulfonate Salt, >99%/O-3077/200 mg
产品编号:O-3077
市  场 价:¥11180.00
场      地:美国(厂家直采)
产品分类: 生化试剂>其他>其他试剂>
联系QQ:1570468124
电话号码:4000-520-616
邮      箱: info@ebiomall.com
美  元  价:$559.00
品      牌: LC Labs
公      司:LC Laboratories
公司分类:
LC Labs/O-3077 Obatoclax, Methanesulfonate Salt, >99%/O-3077/200 mg
商品介绍
  • Obatoclax, also known as GX15-070, is a novel Bcl-2 homology domain-3 (BH3) mimetic. It occupies a hydrophobic cleft within the BH3 binding groove of Bcl-2, antagonizing Bcl-2 and thus inducing apoptosis. Chonghaile, T.N. and Letai, A. "Mimicking the BH3 domain to kill cancer cells." Oncogene 27: S149-S157 (2008).
  • Obatoclax inhibited primary acute myeloid leukemia (AML) progenitor cell proliferation with an average IC50 of 0.18 ± 0.07 µM. Obatoclax potently induced apoptosis in primary AML cells with an average IC50 of 3.6 ± 1.2 µM. Konopleva, M., et al. "Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (Obatoclax)." Cancer Res. 68: 3413-3420 (2008).
  • Obatoclax had a synergistic antitumor effect with the novel BH3 mimetic ABT-737 on inducing apoptosis in OCI-AML3 cells. It also had a synergistic antitumor effect with AraC (1-β-D-arabinofuranosyl cytosine) on inducing apoptosis in leukemic cell lines and primary AML samples. Konopleva, M., et al. "Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (Obatoclax)." Cancer Res. 68: 3413-3420 (2008).
  • Obatoclax overcomes Bcl-2-, Bcl-xL-, Bcl-w-, and Mcl-1-mediated resistance to BAX or BAK. Obatoclax also overcomes the Mcl-1-confered resistance to the BCL-2/BCL-XL/BCL-w-selective antagonist ABT-737 and to the proteasome inhibitor bortezomib. Nguyen, M., et al. "Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis." Proc. Natl. Acad. Sci. USA 104: 19512-19517 (2007).
  • Obatoclax released Bak from Mcl-1 and Bcl-xL and induced apoptosis in mantle cell lymphoma (MCL) cell lines and primary cells from patients with MCL. Obatoclax neutralized bortezomib-induced Mcl-1 accumulation and cooperated with Noxa to induce Bak displacement from this protein, and synergized with bortezomib and sensitized MCL cells to low doses of this proteasome inhibitor. Pérez-Galán, P., et al. "The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak." Blood 109: 4441-4449 (2007).
  • Obatoclax augmented tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis, possibly by releasing Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in human pancreatic cancer cells. Huang, S., et al. "BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells." Clin. Cancer Res. 15: 150-159 (2009).
  • Obatoclax inhibited influenza A virus (IAV) uptake and demonstrated broad-spectrum antiviral activity. Denisova, O.V., et al. "Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza A virus infection." J. Biol. Chem. 287: 35324-35332 (2012).
  • Related CAS number: 803712-67-6 for the free base.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
M.W. 413.49
C20H19N3O•CH4SO3
[803712-79-0]

Storage

Store at or below -20 ºC

Solubility

Soluble in DMSO at 5 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 200-400 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility

Disposal

A
品牌介绍

LC Laboratories公司提供信号转导,调节蛋白亚细胞定位试剂(抗生素)产品蛋白抑制剂产品。热门产品 Bortezomib硼替佐米(99%,97%) Cyclosporine-A环胞霉素A Cyclopamine环巴胺 17-DMAG,Hydrochloride Salt HSP90抑制剂 Everolimus依维莫司 FK-506他克莫司 Forskolin腺苷酸环化酶激活剂 Gefitinib吉非替尼 Leptomycin B细霉素B出核转运抑制剂 LY 294002 PI3-K抑制剂 PD98059 MEK抑制剂 RoscovitineCDK抑制剂 Rapamycin雷帕霉素 SB 202190 MAPK抑制剂 SB203580 P38MAPK抑制剂 SP600125 JNK抑制剂 Staurosporine星孢菌素 UO126 MAPK抑制剂

自营商城图标
厂家直采
全球直采 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔